NPI 1306365689: Open Payments
NPI 1306365689. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,207 in 57 payments from 11 companies in 2025. Trend: 2023 $754 · 2024 $517 · 2025 $1,207
Food & beverage: $1,207
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $239 |
| ABBVIE INC. | 7 | $218 |
| Vanda Pharmaceuticals Inc. | 8 | $180 |
| Neurocrine BioSciences, Inc. | 5 | $146 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $143 |
| Axsome Therapeutics, Inc. | 4 | $92 |
| Lundbeck LLC | 4 | $70 |
| Sage Therapeutics, LLC | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Alkermes, Inc. | 1 | $18 |
Products named: VRAYLAR, REXULTI, HETLIOZ, INGREZZA, CAPLYTA, ABILIFY MAINTENA, Auvelity, ZURZUVAE.
